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See Article, pages 282–289The natural history of cirrhosis is characterised by a silent,
asymptomatic course until increasing portal pressure and
decreasing liver function result in overt clinical signs. In the
asymptomatic phase of the disease, usually referred to as com-
pensated cirrhosis, patients may have good quality of life and
the disease may progress undetected for many years. Median sur-
vival for compensated cirrhosis has been reported in the range of
10–12 years. The progression of the disease is marked by the
development of overt clinical signs, the most frequent of which
are ascites, bleeding, encephalopathy, and jaundice. Following
the ﬁrst appearance of any of these signs, the disease has usually
a more rapid progression towards death or liver transplant. This
more rapid phase of the disease has been designated as ‘‘decom-
pensated cirrhosis’’.
Progression of the decompensated disease may be accelerated
by the development of other complications such as (re)bleeding,
renal impairment (refractory ascites, hepatorenal syndrome),
hepatopulmonary syndrome and sepsis (spontaneous bacterial
peritonitis). The development of hepatocellular carcinoma
(HCC) may accelerate the course of the disease at any stage.
The median survival after decompensation is 2–4 years.
The knowledge of the clinical course of cirrhosis comes
mostly from follow-up studies of patient series observed in sec-
ondary or tertiary care centres. However, the sample size of
these studies has been quite limited [1], while population
based studies of cirrhosis are scanty and therefore generalizabil-
ity of available information on survival of cirrhosis is still
uncertain.
In this issue of the Journal a large population based study of
cirrhosis is reported from England [2], including a cohort of
5118 patients. The cohort has been assembled using two large
electronic databases: the Clinical Practice Research Datalink
(CPRD), which includes over 10 million primary care patients in
the UK, shown to be representative of the population of the UK
[3], and the Hospital Episodes Statistics (HES). This second data-
base comprises records of all admissions conducted in NHS trust
hospitals and independent treatment centres in England. The two
databases were linked in order to identify all the incident cases
either in primary or in secondary care, registered between AprilJournal of Hepatology 20
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By linking the three databases Ratib and coworkers were able
to assess 1- and 5-year average survival of patients with cirrhosis
and the independent effect of hospitalization adjusted for age,
sex, aetiology, and clinical stage of the disease. Overall, survival
probabilities at 1- and 5-years were 0.70 (95% CI 0.69–0.71)
and 0.47 (95% CI 0.45–0.48). Corresponding ﬁgures were 0.84
(95% CI 0.83–0.86) and 0.66 (95% CI 0.63–0.68) for the ambula-
tory group and 0.55 (95% CI 0.53–0.57) and 0.31 (95% CI 0.29–
0.33) following hospitalization, respectively. A hospital admission
for liver disease, substantially impaired prognosis, independent
of stage of cirrhosis (HR = 2.78, 95% CI 2.53, 3.06). Stratiﬁed
analyses by sex, time at risk, aetiology, and age showed that
survival decreased with age, was better for women and was
slightly different across different aetiologies.
A major strength of this large population based study is that it
included patients with incident cirrhosis identiﬁed either in pri-
mary or in secondary care settings, thus assembling a cohort
likely representative of the whole cirrhotic population, at least
in UK. It provides unique and precise (narrow CI) information
on overall survival of cirrhosis, on the incidence of hospitalization
for ambulatory patients and on long term survival after hospital-
ization as well as on survival for patients remaining in an ambu-
latory setting. This information offers solid evidence for health
care policy makers to plan appropriate resources for caring cir-
rhotic patients in UK.
However, applicability of the results in other areas should be
carefully assessed, particularly with respect to the possible differ-
ences in aetiology and related differences in survival. As an exam-
ple, a large population based study of survival of cirrhosis from
Denmark showed very different prevalence of etiology of cirrho-
sis in a cohort of 10,154 hospitalized patients [4], and survival
was markedly different according to aetiology, a ﬁnding different
from the slightly different survival across different etiologies in
the present study.
The key message of the study is that survival of cirrhosis is
signiﬁcantly higher in patients diagnosed and followed in an
ambulatory setting than in patients with a ﬁrst diagnosis in the
occasion of a hospital admission. Therefore the Authors suggest
that any effort should be done to prevent hospitalization to
improve survival.14 vol. 60 j 241–242
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A major drawback of the study is, however, that the electronic
databases used to assemble the included cohort did not contain
any clinical information. Therefore the patient characterization
is largely insufﬁcient to translate the provided prognostic infor-
mation into clinical practice. As an example, an average 1-year
survival probability of 0.84 was estimated for the 2698 ambula-
tory patients. However we know from a number of previous stud-
ies that in mostly compensated patients, like the ambulatory
patients in this study, a large proportion do have oesophageal
varices [1] and a signiﬁcantly lower survival than patients with-
out varices. Moreover, although the ambulatory patients in this
study were mostly compensated, 631 out of 2698 (23%) had a
decompensated cirrhosis, 394 in stage 3 and 237 in stage 4
according to the Baveno IV classiﬁcation [5]. The observed 1-year
survival probability in these two disease stages (decompensated
cirrhosis) is 0.80 and 0.43, respectively [1]. By contrast in stages 1
and 2 (compensated patients without or, respectively, with
oesophageal varices) corresponding probabilities are 0.99 and
0.96 [1]. It is therefore hard to put the average survival probabil-
ity reported by Ratib and coworkers in the clinical context with-
out proper clinical characterization of patients from whom the
estimates were derived and without appropriate subgroup anal-
yses. Furthermore, several prognostic variables are also impor-
tant for decision making. As an example, the knowledge of the
presence of oesophageal varices informs personalized treatment
decisions for the prevention of portal hypertensive bleeding that
have a strong impact on patients outcome and hence on the dis-
ease burden for the health care system. Such kind of personalized
decisions are based on the knowledge of the outcome of
subgroups of patients with certain prognostic characteristics
(varices, in this case) and of the efﬁcacy of treatments (in this
case beta-blockers or banding ligation of varices). The knowledge
of only the average survival probabilities does not allow for any
personalized clinical approach [6]. This consideration points out
another weakness of the study: the lack of any information
regarding the treatments given to the patients not only regarding
the disease complications but also etiological treatments, like
antiviral treatments for HBV or HCV infected patients.
Another major information provided by the Ratib et al. study
is that 1021 of the 2698 (37.8%) ambulatory patients experienced
an emergency hospital admission for liver related episodes.
Unfortunately, no information was available regarding the type
of the clinical events causing such hospital admissions. However,
it is conceivable that hospital admissions were caused by acute
decompensating events, like bleeding or encephalopathy, sponta-
neous bacterial peritonitis, acute on chronic liver failure, or oth-
ers. Therefore, translating the information into actions from the
health care system, may imply prompting adherence to recom-
mendations for the prevention of decompensation in the primary
care setting. As an example of the impact this may have, an Ital-
ian multicentre study of the outcome of variceal bleeding, in the
early 2000s showed that a sizable proportion of patients admit-
ted for bleeding had undergone neither beta-blockers nor band
ligation, when these treatments were clearly recommended [7]:242 Journal of Hepatology 201probably a higher adherence to recommendations for the preven-
tion of variceal bleeding would have saved many of those bleed-
ing episodes.
Finally, the Ratib’s study, for the ﬁrst time, reports post-hospi-
talization survival of cirrhotic patients and shows that hospital-
ization marks a turn point in the clinical course of cirrhosis.
After hospitalization 1- and 5-year survival probabilities were
0.55 and 0.31, respectively, a ﬁgure markedly lower than that
usually reported after the ﬁrst decompensating event. This is
likely due to the fact that hospitalization was associated with
some emergency condition, thus selecting patients with more
severe disease. Again, the lack of any characterization of hospital-
ized patients and of any prognostic subgroups analysis, makes
this information of use only for health care policy makers, while
it may not help personalized decision making.
In summary, the study by Ratib and colleagues provides
important average and precise estimates of survival of cirrhosis
from a large population based study, likely representative of
the cirrhotic population in UK. It also raises, some important con-
siderations. First, large well settled health system administrative
databases may offer the unique opportunity to draw important
information like that provided in the present study; second, this
kind of information may be of use for health care policy makers
who have to plan population oriented health care resources;
third, this kind of information is not any more of use in clinical
practice where an individualized approach to the care of patients
is more and more needed to optimize the efﬁciency of care.Conﬂict of interest
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